Sol-Gel Technologies (SLGL) Profit After Tax (2017 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Profit After Tax of $1.31 for Q1 2026, down 59.06% year-over-year from $3.2 in Q1 2025, and up 100.0% quarter-over-quarter from -$9.3 million in Q4 2025.
Sol-Gel Technologies (SLGL) Profit After Tax (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Profit After Tax for 10 consecutive years, with $1.31 the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 59.06% year-over-year to $1.31; the TTM figure through Mar 2026 stood at $8.3 million (up 160.46% YoY), while the FY2025 annual figure was -$6.1 million, up 42.09% from the prior year.
- Profit After Tax grew to $1.31 in Q1 2026 per SLGL's latest filing, from -$9.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at $11.6 million in Q2 2025 and bottomed at -$15.3 million in Q4 2024.
- Historically, Profit After Tax has averaged -$793940.7 across 5 years, with a median of $0.43 in 2023.
- Annual changes were most pronounced in 2023 — Profit After Tax jumped 59699999900.0% — and 2024, when it slumped 216.67%.
- Sol-Gel Technologies' Profit After Tax stood at -$14.9 million in 2022, then surged by 67.59% to -$4.8 million in 2023, then plunged by 216.67% to -$15.3 million in 2024, then jumped by 39.49% to -$9.3 million in 2025, then jumped by 100.0% to $1.31 in 2026.
- Business Quant data shows SLGL's Profit After Tax at $1.31 in Q1 2026, -$9.3 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 3.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31 |
| Dec 31, 2025 | -9.27 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 11.61 Mn |
| Mar 31, 2025 | 3.20 |
| Dec 31, 2024 | -15.31 Mn |
| Sep 30, 2024 | -366,000.00 |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 2.30 |
| Dec 31, 2023 | -4.84 Mn |
| Sep 30, 2023 | 5.71 Mn |
| Jun 30, 2023 | 5.97 Mn |
| Mar 31, 2023 | 0.43 |
| Dec 31, 2022 | -14.92 Mn |
| Sep 30, 2022 | -0.15 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.24 |
| Dec 31, 2021 | 14.03 Mn |
| Sep 30, 2021 | 1.29 Mn |
| Jun 30, 2021 | 0.35 |